10-K: Quantum-Si Reports Increased Revenue but Continues to Face Net Losses in 2024

Quantum-Si's 2024 10-K filing reveals a revenue increase alongside ongoing net losses as the company progresses with its commercial launch and product development.

Summary

• Quantum-Si Incorporated's 10-K filing for the year ended December 31, 2024, highlights the company's focus on proteomics research tools and its Next-Generation Protein Sequencing (NGPS) technology.
• The company commercially launched its Platinum instrument and began shipping in January 2023, moving to a full commercial launch in the second quarter of 2024.
• In January 2025, Quantum-Si announced the launch of Platinum Pro, with shipments expected by the end of the first quarter of 2025.
• Revenue for 2024 reached $3.1 million, a significant increase from $1.1 million in 2023, but the company still incurred net losses of $101.0 million in 2024, $96.0 million in 2023 and $132.4 million in 2022.
• The company's technology roadmap includes updates to the current platform and a next-generation platform called Proteus, expected to significantly scale sequencing output and workflow automation.
• Quantum-Si is targeting an $8 billion segment of the proteomics research market, focusing on protein identification, expression, and post-translational modifications.
• As of December 31, 2024, the company had cash and cash equivalents and investments in marketable securities totaling $209.6 million.
• The company believes these funds will be sufficient to fund operations for at least the next twelve months.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue is increasing and new products are being launched, significant net losses persist, and the company faces various risks and challenges. The sentiment is neutral, reflecting both positive developments and ongoing concerns.

Positives

• Significant revenue growth from $1.1 million in 2023 to $3.1 million in 2024.
• Launch of new Platinum Pro instrument in January 2025.
• Strong intellectual property portfolio with numerous patents and applications.
• Focus on a large and growing proteomics market with an initial target market of $8 billion.
• Experienced management team with a track record in the life sciences industry.
• Distribution agreement with Avantor to expand market reach in North America.

Negatives

• Continued net losses of $101.0 million in 2024, although losses are decreasing.
• Reliance on contract manufacturers and single-source suppliers poses supply chain risks.
• The life sciences technology market is highly competitive.
• Potential for government regulation of RUO products as medical devices.
• Dependence on research and development spending by academic and research institutions.

Risks

• Inability to generate meaningful revenues or achieve and sustain profitability or positive cash flow.
• Failure to gain commercial traction for current products or successfully launch future products.
• Markets for products may be smaller than estimated, limiting ability to sell products.
• Reliance on contract manufacturers and third-party foundries for key components.
• Potential for government regulation of RUO products as medical devices.
• Cybersecurity incidents could adversely affect the business.
• Geopolitical conflicts could potentially affect sales and disrupt operations.

Future Outlook

The company expects its existing cash and investments, along with revenue from product sales, to be sufficient to fund operations for at least the next 12 months. The company aims to expand its commercial infrastructure, drive evidence generation for NGPS, and continue technical innovation to enhance its product offerings.

Management Comments

• The company's technology roadmap includes updates to the current platform and a next-generation platform called Proteus, expected to significantly scale sequencing output and workflow automation.
• The company aims to continually innovate and deliver new products, product enhancements, applications, workflows, and other tools to enable customers to leverage the power of NGPS at scale.

Industry Context

Quantum-Si operates in the competitive life sciences technology market, competing with established companies like Agilent, Thermo Fisher, and emerging growth companies in proteomics. The company believes its NGPS platform offers a differentiated solution with single-molecule, amino acid-level resolution and automated data analysis.

Comparison to Industry Standards

• The document mentions competitors such as Agilent Technologies, Bio-Rad Laboratories, Danaher, Luminex, Merck KGaA (and its subsidiary MilliporeSigma) and Thermo Fisher Scientific.
• It also mentions emerging growth companies such as Nautilus Biotechnology, Olink Proteomics (acquired by Thermo Fisher Scientific), Quanterix, Seer and Standard BioTools.
• The document claims that there are currently no commercially available NGPS platforms beyond Quantum-Si's Platinum and Platinum Pro systems.
• The document states that legacy proteomics market is largely served by companies that offer a variety of analytical instruments, such as MS and associated reagents and consumables.

Legal Proceedings

• The company is involved in various legal proceedings, claims, investigations and litigation that arise in the ordinary course of its business.
• A punitive class action lawsuit was filed in the Delaware Court of Chancery, styled Farzad v. HighCape Capital, et al., asserting breach of fiduciary duty claims against the former officers and directors of HighCape related to the Business Combination.
• In October 2023, the former contract manufacturer filed a complaint against the Company in the State of Minnesota alleging breach of contract and made claims for economic damage and attorney costs.
• On September 13, 2022, the Company filed a lawsuit against the landlord, alleging that the landlord has: (i) refused to reimburse the Company for costs related to improvements already incurred and submitted; (ii) delayed the Company's completion of improvements, in order to avoid reimbursing the costs of those improvements; and (iii) improperly rejected the Company's proposed improvement plans.

Related Party Transactions

• The Company was a party to the Amended and Restated Technology Services Agreement (the ARTSA) with 4Catalyzer Corporation (4C) and other participant companies controlled by Dr. Jonathan Rothberg, the Chairman of the Company's Board of Directors.
• The Company entered into a Protein Engineering Collaboration (the New Collaboration) with Protein Evolution, Inc. (PEI) to develop technology and methods in the field of nanobodies and potentially other binders to produce novel biological reagents and related data. Dr. Rothberg serves as a member of the board of directors of PEI and the Rothberg family are controlling stockholders of PEI.
• Effective November 1, 2022, the Company entered into an Advisory Agreement with Dr. Rothberg (the Advisory Agreement), pursuant to which Dr. Rothberg previously served as Chairman of the Board, advises the Chief Executive Officer and the Board on strategic matters, and provides consulting, business development and similar services on matters relating to the Company's current, future and potential scientific and strategic initiatives and such other consulting services reasonably requested from time to time.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances.
• Employees experienced workforce reductions as part of the restructuring.
• Customers benefit from new product launches and technological advancements.
• Suppliers may face pressure due to the company's cost-cutting measures and supply chain management.
• Creditors face risks associated with the company's ongoing net losses and dependence on external financing.

Next Steps

• Continue to build direct sales and support infrastructure in the U.S. and Western Europe.
• Pursue commercial partnerships, such as the agreement with Avantor.
• Expand geographic partnerships internationally.
• Provide high-quality technical and scientific support to customers.
• Work with key opinion leaders and generate scientific evidence to support NGPS.
• Offer Pro Mode to enable customers to access technology for custom application development.

Key Dates